Shares of MorphoSys AG (MOR), which have been experiencing strong momentum this year, touched a new 52-week high of $6.85 during intraday trading yesterday.
This global commercial-stage biopharmaceutical company is focused on developing therapies for difficult-to-treat and debilitating types of blood cancer.
The company has one marketed drug by the name Monjuvi, which in combination with Lenalidomide (Revlimid), was granted accelerated approval by the FDA in August 2020 for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Monjuvi, generically known as Tafasitamab, is marketed outside the U.S. by Incyte Corp. (INCY) as Minjuvi.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.